MCID: VLV011
MIFTS: 52

Vulvovaginal Candidiasis

Categories: Infectious diseases, Reproductive diseases

Aliases & Classifications for Vulvovaginal Candidiasis

MalaCards integrated aliases for Vulvovaginal Candidiasis:

Name: Vulvovaginal Candidiasis 12 3 15 17
Candidiasis, Vulvovaginal 45 74
Candidiasis of Vulva and Vagina 12
Candidiasis Vulvovaginal 56
Candidal Vulvovaginitis 12
Monilial Vulvovaginitis 12
Candidal: Cervix 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2272
ICD9CM 36 112.1
MeSH 45 D002181
NCIt 51 C2914
SNOMED-CT 69 72605008
ICD10 34 B37.3
UMLS 74 C0700345

Summaries for Vulvovaginal Candidiasis

CDC : 3 Candidiasis is an infection caused by a yeast (a type of fungus) called Candida. Candida normally lives inside the body (in places such as the mouth, throat, gut, and vagina) and on skin without causing any problems. Sometimes Candida can multiply and cause an infection if the environment inside the vagina changes in a way that encourages its growth. Candidiasis in the vagina is commonly called a “vaginal yeast infection.” Other names for this infection are “vaginal candidiasis,” “vulvovaginal candidiasis,” or “candidal vaginitis.”

MalaCards based summary : Vulvovaginal Candidiasis, also known as candidiasis, vulvovaginal, is related to candidiasis and bacterial vaginosis. An important gene associated with Vulvovaginal Candidiasis is MBL2 (Mannose Binding Lectin 2), and among its related pathways/superpathways are Innate Immune System and Defensins. The drugs Clindamycin and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include skin, cervix and testes, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 A candidiasis that involves fungal infection of the vaginal mucous membranes in women caused by Candida albicans. The symptoms include intense vulval pruritus, burning, erythema and dyspareunia associated with a creamy white, curd-like discharge.

Wikipedia : 77 Vaginal yeast infection, also known as candidal vulvovaginitis and vaginal thrush, is excessive growth... more...

Related Diseases for Vulvovaginal Candidiasis

Diseases related to Vulvovaginal Candidiasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 122)
# Related Disease Score Top Affiliating Genes
1 candidiasis 32.4 CLEC7A DEFB4A MBL2
2 bacterial vaginosis 31.0 DEFB4A MBL2 TLR2
3 oral candidiasis 30.9 DEFB1 DEFB4A
4 vulvar vestibulitis syndrome 29.9 IL1RN MBL2 NLRP3
5 candida glabrata 10.4
6 immunoglobulin g deficiency 10.4 CD79A MBL2
7 coccidioidomycosis 10.4 CLEC7A MBL2
8 immunoglobulin alpha deficiency 10.4 CD79A MBL2
9 trichomoniasis 10.3
10 corneal abscess 10.3 DEFB1 DEFB4A
11 osteonecrosis of the jaw 10.3 DEFB1 DEFB4A
12 clonorchiasis 10.3 CD79A IL2
13 diabetes mellitus 10.3
14 vulvovaginitis 10.3
15 prosthetic joint infection 10.3 MBL2 TLR2
16 cervicitis 10.2 DEFB4A IL2
17 tularemia 10.2 MBL2 TLR2
18 fungal keratitis 10.2 CLEC7A TLR2
19 haemophilus influenzae 10.2 CLEC7A TLR2
20 hematopoietic stem cell transplantation 10.2 CLEC7A IL2
21 localized scleroderma 10.2 DEFB1 DEFB4A
22 mycobacterium kansasii 10.2 NLRP3 TLR2
23 congenital hypogammaglobulinemia 10.2 CD79A IL4
24 septic arthritis 10.2 DEFB4A TLR2
25 immunodeficiency with hyper-igm, type 1 10.2 CD79A IL4
26 chromoblastomycosis 10.2 CLEC7A IL4
27 orofacial granulomatosis 10.2 CD79A IL4
28 allergic bronchopulmonary aspergillosis 10.1 IL4 MBL2
29 wells syndrome 10.1 IL2 NLRP3
30 folliculitis 10.1 DEFB4A IL4
31 milk allergy 10.1 CD79A IL4
32 cryptococcosis 10.1 IL4 MBL2
33 virus associated hemophagocytic syndrome 10.1 IL2 IL4
34 autoimmune vasculitis 10.1 IL2 IL4
35 invasive aspergillosis 10.1 CLEC7A MBL2 TLR2
36 jak3-deficient severe combined immunodeficiency 10.1 IL2 IL4
37 atopic keratoconjunctivitis 10.1 IL2 IL4
38 angiostrongyliasis 10.1 IL2 IL4
39 rheumatic fever 10.1 IL2 MBL2
40 proliferative glomerulonephritis 10.1 CD79A IL4
41 autoimmune gastritis 10.1 IL2 IL4
42 sebaceous gland disease 10.1 CD79A DEFB4A TLR2
43 conjunctival disease 10.1 IL4 NLRP3
44 ocular cicatricial pemphigoid 10.1 CD79A IL4
45 osteosclerotic myeloma 10.1 CD79A IL1RN
46 meningococcemia 10.1 IL1RN MBL2
47 coccidiosis 10.1 IL2 IL4
48 filarial elephantiasis 10.0 IL4 TLR2
49 severe combined immunodeficiency, x-linked 10.0 IL2 IL4
50 meningitis 10.0 MBL2 NLRP3 TLR2

Comorbidity relations with Vulvovaginal Candidiasis via Phenotypic Disease Network (PDN): (show all 12)


Acute Cystitis Anxiety
Bronchitis Decubitus Ulcer
Deficiency Anemia Esophagitis
Heart Disease Hypertension, Essential
Hypothyroidism Oral Candidiasis
Osteoporosis Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Vulvovaginal Candidiasis:



Diseases related to Vulvovaginal Candidiasis

Symptoms & Phenotypes for Vulvovaginal Candidiasis

GenomeRNAi Phenotypes related to Vulvovaginal Candidiasis according to GeneCards Suite gene sharing:

27 (show all 23)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-101 9.75 CLEC7A DEFB1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-103 9.75 CLEC7A
3 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.75 IL1RN
4 Increased shRNA abundance (Z-score > 2) GR00366-A-107 9.75 CLEC7A
5 Increased shRNA abundance (Z-score > 2) GR00366-A-12 9.75 CLEC7A
6 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.75 IL1RN
7 Increased shRNA abundance (Z-score > 2) GR00366-A-128 9.75 CLEC7A
8 Increased shRNA abundance (Z-score > 2) GR00366-A-135 9.75 CLEC7A
9 Increased shRNA abundance (Z-score > 2) GR00366-A-143 9.75 CLEC7A
10 Increased shRNA abundance (Z-score > 2) GR00366-A-147 9.75 CLEC7A
11 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.75 CLEC7A
12 Increased shRNA abundance (Z-score > 2) GR00366-A-158 9.75 CLEC7A DEFB1 IL1RN
13 Increased shRNA abundance (Z-score > 2) GR00366-A-164 9.75 CLEC7A
14 Increased shRNA abundance (Z-score > 2) GR00366-A-186 9.75 CLEC7A
15 Increased shRNA abundance (Z-score > 2) GR00366-A-202 9.75 CLEC7A
16 Increased shRNA abundance (Z-score > 2) GR00366-A-205 9.75 CLEC7A
17 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.75 CLEC7A
18 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.75 CLEC7A
19 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.75 CLEC7A IL1RN
20 Increased shRNA abundance (Z-score > 2) GR00366-A-57 9.75 CLEC7A
21 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.75 CLEC7A DEFB1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.75 CLEC7A
23 Increased shRNA abundance GR00327-A 9.26 CD79A DEFB1 IL1RN IL4

MGI Mouse Phenotypes related to Vulvovaginal Candidiasis:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.97 CD101 CD79A CLEC7A IL1RN IL2 IL4
2 homeostasis/metabolism MP:0005376 9.86 CD79A CLEC7A IL1RN IL2 IL4 MBL2
3 immune system MP:0005387 9.81 CD101 CD79A CLEC7A IL1RN IL2 IL4
4 liver/biliary system MP:0005370 9.35 CD79A IL2 IL4 NLRP3 TLR2
5 renal/urinary system MP:0005367 9.02 CD79A IL4 MBL2 NLRP3 TLR2

Drugs & Therapeutics for Vulvovaginal Candidiasis

Drugs for Vulvovaginal Candidiasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 84)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clindamycin Approved, Vet_approved Phase 4,Phase 3,Early Phase 1,Not Applicable 18323-44-9 29029
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
3
Clotrimazole Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 23593-75-1 2812
4
Fluconazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 86386-73-4 3365
5
Metronidazole Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 443-48-1 4173
6
Dequalinium Approved, Investigational Phase 4 6707-58-0
7
Terconazole Approved Phase 4,Phase 3,Not Applicable,Early Phase 1 67915-31-5 441383
8
Tinidazole Approved, Investigational Phase 4,Phase 3 19387-91-8 5479
9
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
10 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
11 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
12 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
13 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
14 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
15 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
16 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
17 Antibiotics, Antitubercular Phase 4,Phase 3,Not Applicable
18 Antitubercular Agents Phase 4,Phase 3
19 Clindamycin palmitate Phase 4,Phase 3,Early Phase 1,Not Applicable
20 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
21 Clindamycin phosphate Phase 4,Phase 3,Early Phase 1,Not Applicable
22 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
23 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Cytochrome P-450 CYP2C19 Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
25 Anti-Infective Agents, Local Phase 4,Phase 3
26 Immune Sera Phase 4
27 Immunologic Factors Phase 4,Phase 3,Phase 1,Phase 2
28
Tetracycline Approved, Vet_approved Phase 3 60-54-8 5353990
29
Amphotericin B Approved, Investigational Phase 3,Phase 2 1397-89-3 5280965 14956
30
Ketoconazole Approved, Investigational Phase 3 65277-42-1 47576
31
Azithromycin Approved Phase 3 83905-01-5 447043 55185
32
Rifabutin Approved, Investigational Phase 3 72559-06-9 46783538 6323490
33
leucovorin Approved Phase 3 58-05-9 143 6006
34
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
35
Secnidazole Approved Phase 3 3366-95-8
36
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
37 Antiprotozoal Agents Phase 3,Phase 2,Not Applicable,Early Phase 1
38 Antiparasitic Agents Phase 3,Phase 2,Not Applicable,Early Phase 1
39 Liposomal amphotericin B Phase 3,Phase 2
40 Alkylating Agents Phase 3
41 Dermatologic Agents Phase 3
42 Antirheumatic Agents Phase 3
43 Folic Acid Antagonists Phase 3
44 Antimetabolites, Antineoplastic Phase 3
45 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
46 Vitamin B9 Phase 3
47 Folate Phase 3
48 Vitamin B Complex Phase 3
49 Antimetabolites Phase 3
50 Immunosuppressive Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 70)
# Name Status NCT ID Phase Drugs
1 Use of Boric Acid in Combination With Probiotics for the Treatment of Vaginal Infections Unknown status NCT02860845 Phase 4 Antibiotic (Clindamycin);Antifungal (Clotrimazole)
2 Comparative Efficacy Study of 10 mg Dequalinium Chloride (Fluomizin) in the Treatment of Vulvovaginal Candidiasis Completed NCT02242695 Phase 4 Fluomizin vaginal tablets;Canesten vaginal tablets
3 Epidemiological Study About the Evolution of Patients Treated for an Acute Episode of Vulvovaginal Candidiasis Completed NCT02248506 Phase 4
4 Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis Completed NCT02180100 Phase 4 Terconazole Vaginal Suppository;Fluconazole
5 Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis Completed NCT02180828 Phase 4 Clotrimazole vaginal tablet;Fluconazole
6 Effect of Exercise on Spread of the Miconozole Nitrate OVULE in the Vagina Completed NCT00194324 Phase 4 Miconazole nitrate
7 Lactoserum (Dermacyd Femina®) and Prevention of Recurrence of Bacterial Vaginosis Completed NCT00556179 Phase 4 Lactoserum (Dermacyd Femina®)
8 Evaluation of Efficacy and Safety of Gynomax® XL Ovule Not yet recruiting NCT03839875 Phase 4 Gynomax® XL Vaginal Ovule
9 The Study Of Fluconazole For Vulvovaginal Candidiasis Completed NCT01806623 Phase 3 Fluconazole
10 Diabetes Mellitus and Vulvovaginal Candidiasis Completed NCT00353561 Phase 3 Boric;Fluconazole
11 ProF-001_Phase IIa Completed NCT03115073 Phase 2, Phase 3 Candiplus;Clotrimazole
12 Study of the Efficacy and Tolerance of Intra-vaginal Treatment With a Total Freeze-dried Culture of Lcr Regenerans® in the Prevention of Relapses of Recurrent Vulvovaginal Candidiasis Completed NCT02251093 Phase 3 Lcr Regenerans;Placebo
13 A Study to Compare the Efficacy and Safety of a Combination of Ketoconazole and Clindamycin Compared to Tetracycline/Amphotericin B Combination Cream for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis (P08077) Completed NCT01293643 Phase 3 100 mg clindamycin /800 mg ketoconazole vaginal ovule;100 mg tetracycline hydrochloride /50 mg amphotericin B cream
14 Comparative Efficacy of Ovule vs Tablet Completed NCT00755053 Phase 3 Clotrimazole, vaginal ovule;Clotrimazole, vaginal tablet
15 A Randomized Study of Daily and Intermittent Prophylactic Regimens for the Prevention of Disseminated Mycobacterium Avium Complex (MAC) and Fungal Infections in HIV-Infected Patients Completed NCT00002122 Phase 3 Azithromycin;Rifabutin;Fluconazole
16 Study of the Management of Vaginal Discharge in West African Using Single Dose Treatments Completed NCT00313131 Phase 3 tinidazole+fluconazole vs metronidazole+clotrimazole
17 A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants Completed NCT01941940 Phase 3 Tocilizumab;DMARDs
18 Safety and Clinical and Microbiological Efficacy of the Combination of Fluconazole and Secnidazole for the Treatment of Symptomatic Vaginal Discharge Completed NCT02111629 Phase 3 Fluconazole and Secnidazole
19 A Study of Oral VT-1161 for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) Recruiting NCT03562156 Phase 3 VT-1161;Placebo
20 A Study of Oral VT-1161 for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) Recruiting NCT03561701 Phase 3 VT-1161;Placebo
21 A Study of Oral VT-1161 for the Treatment of Acute Vaginal Candidiasis (Yeast Infection) in Patients With Recurrent Vaginal Candidiasis Recruiting NCT03840616 Phase 3 VT-1161 150 mg capsule;Fluconazole 150 mg
22 Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis Recruiting NCT03734991 Phase 3 Ibrexafungerp;Placebo
23 Treatment of Candidal Vulvovaginitis Using Cumin Seed Extract Vaginal Cream. Recruiting NCT03005353 Phase 2, Phase 3 Cumin seed extract;clotrimazole
24 Ketoconazole Gel Versus Terconazole Cream for Vaginal Candidiasis Not yet recruiting NCT03473418 Phase 3 Ketoconazole;Terconazole
25 Efficacy, Safety LactiSal 1% Gel, LactSal 50 mg, Clotrimazole 100 mg Tablet in Treatment Vulvovaginal Candidiasis Withdrawn NCT02907307 Phase 3 Clotrimazole vaginal tablet 100mg
26 A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) Completed NCT02267382 Phase 2 VT-1161;Placebo
27 Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis Completed NCT01926028 Phase 1, Phase 2
28 MGCD290 and Fluconazole Versus Fluconazole Alone for the Treatment of Moderate to Severe Vulvovaginal Candidiasis Completed NCT01497223 Phase 2 MGCD290
29 Safety and Efficacy of Oral SCY-078 vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis Completed NCT02679456 Phase 2 SCY-078;Fluconazole
30 An Active-Controlled, Dose-Finding Study of SCY-078 vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis Completed NCT03253094 Phase 2 Fluconazole;SCY-078
31 Arasertaconazole Nitrate Pessaries - Dose Finding Study for the Vulvovaginal Candidiasis (VVC) Treatment Completed NCT01144286 Phase 2 arasertaconazole nitrate;placebo
32 A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection) Completed NCT01891331 Phase 2 VT-1161;Fluconazole
33 Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC) Completed NCT02971007 Phase 2 Oral Encochleated Amphotericin B (CAMB);Fluconazole
34 Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories for Preventing Vaginal Infections in HIV-seronegative Women Completed NCT01230814 Phase 2 Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate);Placebo
35 RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections Completed NCT02733432 Phase 2 CD101 Vaginal Gel (3%);CD101 External gel (1%);CD101 Vaginal Ointment (6%);CD101 External ointment (1%);Fluconazole
36 TOL-463 Phase 2 Study for Vaginitis Completed NCT02866227 Phase 2 TOL-463;TOL-463
37 Safety and Efficacy Study of Lactobacillus Administered Vaginally in Women With Bacterial Vaginosis Completed NCT00635622 Phase 2 LACTIN-V;Placebo control substance
38 Patients With Vulvovaginal Candidiasis Recruiting NCT03024502 Phase 1, Phase 2 EPP-AF Gel 1%;EPP-AF Gel 2%;Clotrimazole
39 Placebo-Controlled Study Of TOL-463 Insert for Suppression Of Bacterial Vaginosis (BV) Not yet recruiting NCT03930745 Phase 2 TOL-463
40 Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection Terminated NCT01199731 Phase 2 GSK2248761 100 mg once daily;GSK2248761 200 mg once daily;Etravirine
41 Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis Withdrawn NCT03167957 Phase 2 Oral Encochleated Amphotericin B (CAMB);Oral Encochleated Amphotericin B (CAMB)
42 Use of Oral Probiotics as an Adjunctive Therapy to Fluconazole in the Treatment of Yeast Vaginitis Unknown status NCT00479947 Phase 1 Probiotics (Natural product);Probiotics (L. rhamnosus GR-1 and L. reuteri RC-14)
43 Safety and Immunogenicity Study of a Virosomal Vaccine Against Recurrent Vulvovaginal Candida Infection Completed NCT01067131 Phase 1
44 Evaluation of Intravaginal Gel and Ovule Formulations of TOL-463 Completed NCT01812889 Phase 1 TOL-463 Vaginal ovule;TOL-463 Vaginal gel
45 Study Evaluating the Optimal Dosage for Equivalence Between Lcr Regenerans® Capsules and Tablets (Lactobacillus Rhamnosus Lcr35®) on the Vaginal Flora Colonisation Completed NCT02730494 Phase 1
46 Use of 405nm Blue Light Emitting Diode in the Treatment of Women With Vulvovaginal Candidiasis: a Clinical Trial Unknown status NCT03075046 Not Applicable
47 Will Vaginal Colonization of Lactobacillus Increase Cure Rate After Treatment of Bacterial Vaginosis and Chronic Vulvovaginal Candida Unknown status NCT02295579
48 Rwanda VMB Restoration Study Unknown status NCT02459665 Not Applicable Prophylactic use of metronidazole pills (500 mg)
49 Diagnosing Bacterial Vaginosis/Vaginitis (BV) Using the Gynecologene Test Method Unknown status NCT02558179
50 Diabetes Mellitus With Pregnancy in Benisuef Localities Unknown status NCT03169205

Search NIH Clinical Center for Vulvovaginal Candidiasis

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: candidiasis, vulvovaginal

Genetic Tests for Vulvovaginal Candidiasis

Anatomical Context for Vulvovaginal Candidiasis

MalaCards organs/tissues related to Vulvovaginal Candidiasis:

42
Skin, Cervix, Testes, Colon, Neutrophil, B Cells, Tonsil

Publications for Vulvovaginal Candidiasis

Articles related to Vulvovaginal Candidiasis:

(show top 50) (show all 466)
# Title Authors Year
1
Safety and Efficacy of a Novel Vaginal Anti-infective, TOL-463, in the Treatment of Bacterial Vaginosis and Vulvovaginal Candidiasis: A Randomized, Single-blind, Phase 2, Controlled Trial. ( 30184181 )
2019
2
Probiotics for Oral and Vulvovaginal Candidiasis: A Review. ( 31112355 )
2019
3
Alternative and complementary therapies for vulvovaginal candidiasis. ( 30269301 )
2019
4
Vulvovaginal candidiasis: histologic lesions are primarily polymicrobial and invasive and do not contain biofilms. ( 30595144 )
2019
5
Enhanced antifungal activity of bovine lactoferrin-producing probiotic Lactobacillus casei in the murine model of vulvovaginal candidiasis. ( 30621597 )
2019
6
Impaired Th17 cell proliferation and decreased pro-inflammatory cytokine production in CXCR3/CXCR4 double-deficient mice of vulvovaginal candidiasis. ( 30656691 )
2019
7
Comparing the effectiveness of Salvia officinalis, clotrimazole and their combination on vulvovaginal candidiasis: A randomized, controlled clinical trial. ( 30663184 )
2019
8
Intravaginal Delivery of Syngonanthus nitens (Bong.) Ruhland Fraction Based on a Nanoemulsion System Applied to Vulvovaginal Candidiasis Treatment. ( 30890237 )
2019
9
CD101 Topical Compared With Oral Fluconazole for Acute Vulvovaginal Candidiasis: A Randomized Controlled Trial. ( 30893271 )
2019
10
Current patient perspectives of vulvovaginal candidiasis: incidence, symptoms, management and post-treatment outcomes. ( 30925872 )
2019
11
Ultraviolet A/blue light-emitting diode therapy for vulvovaginal candidiasis: a case presentation. ( 30945022 )
2019
12
Antifungal Susceptibility Profile of Candida Albicans Isolated from Vulvovaginal Candidiasis in Xinjiang Province of China. ( 30968320 )
2019
13
Reply to Vulvovaginal Candidiasis: Histologic lesions are primarily polymicrobial and invasive and do not contain biofilms. ( 31029661 )
2019
14
Questions remain regarding the presence of fungal species biofilm in women with vulvovaginal candidiasis. ( 31029662 )
2019
15
Antifungal susceptibilities, in vitro production of virulence factors and activities of ceragenins against Candida spp. isolated from vulvovaginal candidiasis. ( 29846682 )
2019
16
The changes of antifungal susceptibilities caused by the phenotypic switching of Candida species in 229 patients with vulvovaginal candidiasis. ( 30101450 )
2019
17
Development, characterization, and in vitro-in vivo evaluation of polymeric nanoparticles containing miconazole and farnesol for treatment of vulvovaginal candidiasis. ( 29361177 )
2019
18
Longitudinal trajectory of vulvovaginal candidiasis, trichomoniasis, and bacterial vaginosis during pregnancy as well as the impact on pregnancy outcomes: a preliminary study. ( 29685081 )
2018
19
Thymol, eugenol and lactobacilli in a medical device for the treatment of bacterial vaginosis and vulvovaginal candidiasis. ( 29874389 )
2018
20
Candida africana in recurrent vulvovaginal candidiasis (RVVC) patients: frequency and phenotypic and genotypic characteristics. ( 30248002 )
2018
21
Natural Products for Vulvovaginal Candidiasis Treatment: Evidence from Clinical Trials. ( 30277156 )
2018
22
Inhibition of CXCR4 by MicroRNA-1192 Reduces the Activation of Th17 Cells and Expression of Inflammation Factors in a Mouse Model of Vulvovaginal Candidiasis. ( 30355939 )
2018
23
Nystatin enhances the immune response against Candida albicans and protects the ultrastructure of the vaginal epithelium in a rat model of vulvovaginal candidiasis. ( 30359236 )
2018
24
Efficacy of antifungal drugs in the treatment of vulvovaginal candidiasis: a Bayesian network meta-analysis. ( 30425538 )
2018
25
Biofilms and vulvovaginal candidiasis. ( 30447520 )
2018
26
In vivo applicability of Neosartorya fischeri antifungal protein 2 (NFAP2) in treatment of vulvovaginal candidiasis. ( 30478163 )
2018
27
Miconazole loaded chitosan-based nanoparticles for local treatment of vulvovaginal candidiasis fungal infections. ( 30481701 )
2018
28
Concerns regarding bias in estimates of recurrent vulvovaginal candidiasis. ( 30507400 )
2018
29
IL-9 Integrates the Host-Candida Cross-Talk in Vulvovaginal Candidiasis to Balance Inflammation and Tolerance. ( 30515173 )
2018
30
Influence of Nursing Intervention on Recurrent Vulvovaginal Candidiasis Patients Treated with ATP-infrared Bio-effect Technique. ( 30524981 )
2018
31
Types of yeasts that cause vulvovaginal candidiasis in chronic users of corticosteroids. ( 30544194 )
2018
32
Randomized clinical trial in women with Recurrent Vulvovaginal Candidiasis: efficacy of probiotics and lactoferrin as maintenance treatment. ( 30565745 )
2018
33
RISK FACTORS OF VULVOVAGINAL CANDIDIASIS IN DERMATO-VENEREOLOGY OUTPATIENTS CLINIC OF SOETOMO GENERAL HOSPITAL, SURABAYA, INDONESIA. ( 29619437 )
2018
34
A Fungal Immunotherapeutic Vaccine (NDV-3A) for Treatment of Recurrent Vulvovaginal Candidiasis-A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial. ( 29697768 )
2018
35
A Therapeutic Vaccine for Recurrent Vulvovaginal Candidiasis. ( 29697770 )
2018
36
Pulsatilla decoction inhibits Candida albicans proliferation and adhesion in a mouse model of vulvovaginal candidiasis via the Dectin-1 signaling pathway. ( 29775695 )
2018
37
Risk of major congenital malformations following first-trimester exposure to vaginal azoles used for treating vulvovaginal candidiasis: a population-based retrospective cohort study. ( 29790255 )
2018
38
Mannose-Binding Lectin Gene Polymorphism and Its Association with Susceptibility to Recurrent Vulvovaginal Candidiasis. ( 29850562 )
2018
39
Vulvovaginal candidiasis: species distribution of Candida and their antifungal susceptibility pattern. ( 29902998 )
2018
40
Antimicrobial photodynamic therapy as a new approach for the treatment of vulvovaginal candidiasis: preliminary results. ( 29931589 )
2018
41
Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species. ( 29932786 )
2018
42
Amphotericin B-Loaded Poly(lactic-co-glycolic acid) Nanofibers: An Alternative Therapy Scheme for Local Treatment of Vulvovaginal Candidiasis. ( 29940181 )
2018
43
Human Anti-Als3p Antibodies Are Surrogate Markers of NDV-3A Vaccine Efficacy Against Recurrent Vulvovaginal Candidiasis. ( 29963049 )
2018
44
Long-Term Outcomes of Women With Recurrent Vulvovaginal Candidiasis After a Course of Maintenance Antifungal Therapy. ( 29975334 )
2018
45
Risk Factors of Vulvovaginal Candidiasis among Women of Reproductive Age in Xi'an: A Cross-Sectional Study. ( 29977925 )
2018
46
Contribution of TLR2 pathway in the pathogenesis of vulvovaginal candidiasis. ( 30052917 )
2018
47
Epitope unmasking in vulvovaginal candidiasis is associated with hyphal growth and neutrophilic infiltration. ( 30063729 )
2018
48
Vulvovaginal candidiasis in reproductive age women in Enugu Nigeria, clinical versus laboratory-assisted diagnosis. ( 30074004 )
2018
49
Global burden of recurrent vulvovaginal candidiasis: a systematic review. ( 30078662 )
2018
50
Vaginal lipidomics of women with vulvovaginal candidiasis and cytolytic vaginosis: A non-targeted LC-MS pilot study. ( 30133508 )
2018

Variations for Vulvovaginal Candidiasis

Expression for Vulvovaginal Candidiasis

Search GEO for disease gene expression data for Vulvovaginal Candidiasis.

Pathways for Vulvovaginal Candidiasis

Pathways related to Vulvovaginal Candidiasis according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.96 CD101 CD79A CLEC7A DEFB1 DEFB4A IL1RN
2
Show member pathways
12.06 DEFB1 DEFB4A TLR2
3
Show member pathways
12.03 DEFB4A IL4 TLR2
4 11.87 CD79A IL1RN IL2 IL4 TLR2
5
Show member pathways
11.85 CLEC7A IL2 NLRP3
6
Show member pathways
11.8 DEFB4A IL4 TLR2
7 11.73 CLEC7A MBL2 TLR2
8 11.56 CD79A IL2 IL4
9 11.34 CD101 IL2 IL4
10 11.18 IL1RN IL2 IL4
11 11.03 IL2 IL4
12 10.96 IL2 IL4
13 10.89 IL2 IL4
14 10.85 NLRP3 TLR2

GO Terms for Vulvovaginal Candidiasis

Cellular components related to Vulvovaginal Candidiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.43 DEFB1 DEFB4A IL1RN IL2 IL4 MBL2
2 extracellular region GO:0005576 9.17 DEFB1 DEFB4A IL1RN IL2 IL4 MBL2

Biological processes related to Vulvovaginal Candidiasis according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.73 CLEC7A IL1RN NLRP3 TLR2
2 innate immune response GO:0045087 9.72 CLEC7A DEFB1 MBL2 NLRP3 TLR2
3 defense response to bacterium GO:0042742 9.7 DEFB1 DEFB4A MBL2
4 defense response GO:0006952 9.63 DEFB1 DEFB4A NLRP3
5 immune system process GO:0002376 9.63 CD79A CLEC7A IL2 MBL2 NLRP3 TLR2
6 positive regulation of B cell proliferation GO:0030890 9.51 IL2 IL4
7 B cell activation GO:0042113 9.49 CD79A IL4
8 positive regulation of T cell differentiation GO:0045582 9.48 IL2 IL4
9 immune response GO:0006955 9.43 DEFB1 DEFB4A IL1RN IL2 IL4 TLR2
10 positive regulation of isotype switching to IgG isotypes GO:0048304 9.4 IL2 IL4
11 positive regulation of interleukin-13 production GO:0032736 9.37 IL4 NLRP3
12 cytokine secretion involved in immune response GO:0002374 9.26 NLRP3 TLR2
13 defense response to Gram-positive bacterium GO:0050830 9.02 DEFB1 DEFB4A MBL2 NLRP3 TLR2

Molecular functions related to Vulvovaginal Candidiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 carbohydrate binding GO:0030246 9.5 CLEC7A IL2 MBL2
2 cytokine activity GO:0005125 9.43 IL1RN IL2 IL4
3 peptidoglycan binding GO:0042834 9.16 NLRP3 TLR2
4 signaling pattern recognition receptor activity GO:0008329 8.96 CLEC7A TLR2
5 CCR6 chemokine receptor binding GO:0031731 8.62 DEFB1 DEFB4A

Sources for Vulvovaginal Candidiasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....